Literature DB >> 30481504

Orexin as a modulator of fear-related behavior: Hypothalamic control of noradrenaline circuit.

Shingo Soya1, Takeshi Sakurai2.   

Abstract

Fear is an important physiological function for survival. It appears when animals or humans are confronted with an environmental threat. The amygdala has been shown to play a highly important role in emergence of fear. Hypothalamic orexin neurons are activated by fearful stimuli to evoke a 'defense reaction' with an increase in arousal level and sympathetic outflow to deal with the imminent danger. However, how this system contributes to the emergence of fear-related behavior is not well understood. Orexin neurons in the hypothalamus send excitatory innervations to noradrenergic neurons in the locus coeruleus (NALC) which express orexin receptor 1 (OX1R) and send projections to the lateral amygdala (LA). Inhibition of this di-synaptic orexin → NALC → LA pathway by pharmacological or opto/chemogenetic methods reduces cue-induced fear expression. Excitatory manipulation of this pathway induces freezing, a fear-related behavior that only occurs when the environment contains some elements suggestive of danger. Although, fear memory helps animals respond to a context or cue previously paired with an aversive stimulus, fear-related behavior is sometimes evoked even in a distinct context containing some similar elements, which is known as fear generalization. Our recent observation suggests that the orexin → NALC → LA pathway might contribute to this response. This review focuses on recent advances regarding the role of hypothalamic orexin neurons in behavioral fear expression. We also discuss the potential effectiveness of orexin receptor antagonists for treating excessive fear response or overgeneralization seen in anxiety disorder and post-traumatic stress disorder (PTSD).
Copyright © 2018. Published by Elsevier B.V.

Entities:  

Keywords:  Anxiety; Arousal; Fear; Orexin; Panic disorder; Post-traumatic stress disorder

Mesh:

Substances:

Year:  2018        PMID: 30481504     DOI: 10.1016/j.brainres.2018.11.032

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  8 in total

1.  Introduction to the Special Issue: "Making orexin-based therapies for addiction a reality: What are the steps from here?"

Authors:  Morgan H James; Gary Aston-Jones
Journal:  Brain Res       Date:  2020-01-10       Impact factor: 3.252

2.  Common pathways and communication between the brain and heart: connecting post-traumatic stress disorder and heart failure.

Authors:  Marlene A Wilson; Israel Liberzon; Merry L Lindsey; Yana Lokshina; Victoria B Risbrough; Renu Sah; Susan K Wood; John B Williamson; Francis G Spinale
Journal:  Stress       Date:  2019-06-04       Impact factor: 3.493

Review 3.  Exploring the Role of Orexinergic Neurons in Parkinson's Disease.

Authors:  Sachin Kumar; Tapan Behl; Aayush Sehgal; Sukhbir Singh; Neelam Sharma; Saurabh Bhatia; Ahmed Al-Harassi; Mohammed M Abdel-Daim; Simona Bungau
Journal:  Neurotox Res       Date:  2021-09-08       Impact factor: 3.911

4.  Contextual generalization of social stress learning is modulated by orexin receptors in basolateral amygdala.

Authors:  Jazmine D W Yaeger; Kevin T Krupp; Tangi R Summers; Cliff H Summers
Journal:  Neuropharmacology       Date:  2022-06-17       Impact factor: 5.273

Review 5.  The orexin (hypocretin) neuropeptide system is a target for novel therapeutics to treat cocaine use disorder with alcohol coabuse.

Authors:  Morgan H James; Jennifer E Fragale; Shayna L O'Connor; Benjamin A Zimmer; Gary Aston-Jones
Journal:  Neuropharmacology       Date:  2020-10-19       Impact factor: 5.250

6.  Sleep disturbance at pre-deployment is a significant predictor of post-deployment re-experiencing symptoms.

Authors:  Dean T Acheson; Brian Kwan; Adam X Maihofer; Victoria B Risbrough; Caroline M Nievergelt; Jacob W Clark; Xin M Tu; Michael R Irwin; Dewleen G Baker
Journal:  Eur J Psychotraumatol       Date:  2019-10-29

Review 7.  Nonclinical pharmacology of daridorexant: a new dual orexin receptor antagonist for the treatment of insomnia.

Authors:  Catherine Roch; Giorgio Bergamini; Michel A Steiner; Martine Clozel
Journal:  Psychopharmacology (Berl)       Date:  2021-08-20       Impact factor: 4.530

8.  Lateral hypothalamus involvement in control of stress response by bed nucleus of the stria terminalis endocannabinoid neurotransmission in male rats.

Authors:  Lucas Gomes-de-Souza; Willian Costa-Ferreira; Michelle M Mendonça; Carlos H Xavier; Carlos C Crestani
Journal:  Sci Rep       Date:  2021-08-09       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.